Drugs and Protein - Clinical Research Informer

Lilly puts more money into protein degradation

Bio Pharma Dive

AUGUST 25, 2021

The pharma has struck its second research pact focused on drugs that break down harmful proteins in as many years, this time with California biotech Lycia Therapeutics.

Protein

Protein Drugs Research

ALS drugmakers, encouraged by recent FDA feedback, set their sights on a key protein

Bio Pharma Dive

MARCH 27, 2023

A closely watched meeting showed the FDA’s own external advisers think that effects on this protein, known as neurofilament, could be enough to warrant conditional approval of certain drugs.

Protein

Protein Drugs

GPCR-targeting drugs: A renewed focus on a ubiquitous group of proteins

Bio Pharma Dive

MARCH 7, 2023

As many as a third of FDA-approved drugs target GPCRs in some fashion, with uses ranging from treating cancer to pain. But biotech startups say there is still room to develop more.

Protein

Protein FDA Approval Drugs Development

Touting a new way to drug an all-important family of proteins, a startup launches with $100M

Bio Pharma Dive

JANUARY 27, 2022

Backed by some of biotech's most powerful investors, Septerna is looking to usher in the next chapter of medicines that act on G protein-coupled receptors.

Protein

Protein Medicine Drugs

Gladstone and UCSF scientists discover BET protein role in Covid-19

Pharmaceutical Technology

JULY 20, 2022

Researchers at Gladstone Institutes and UC San Francisco (UCSF) have discovered in a study that bromodomain and extraterminal (BET) proteins are vital for the body to fight Covid-19 infection. . The research also found that BET proteins play two distinct roles in affecting how the SARS-CoV-2 virus interacts with human cells. .

Protein

Protein Scientist Gene DNA

AbbVie, targeting a well-known protein family, expands a partnership into neuroscience

Bio Pharma Dive

AUGUST 2, 2022

It’s the second deal in as many years between AbbVie and Sosei Heptares, which together have been trying to develop drugs that target so-called G protein-coupled receptors.

Protein

Protein Development Drugs

Feinstein Institutes researchers discover new protein for sepsis treatment

Pharmaceutical Technology

FEBRUARY 6, 2023

Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis. Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections.

Protein

Protein Research Antibody Immune Response

Pfizer stocks cancer drug pipeline with $2.3B deal for Trillium

Bio Pharma Dive

AUGUST 23, 2021

The acquisition reflects growing industry interest in the cancer-linked protein targeted by Trillium's drugs, most notably shown by Gilead's acquisition of Forty Seven last year.

Drugs

Drugs Protein

Teva puts rival to Prometheus, Pfizer drugs at center of turnaround plans

Bio Pharma Dive

MAY 18, 2023

At an investor day, executives highlighted an experimental inflammatory disease drug targeting the protein TL1A as important to their long-term growth prospects.

Drugs

Drugs Protein

Biogen, Ionis shelve ALS drug following study failure

Bio Pharma Dive

MAY 16, 2024

While results indicated the drug works as intended, it didn’t have enough of an effect on a protein that’s become integral to many ALS research programs.

Drugs

Drugs Protein Research

J&J-backed startup launches with $100M to build better brain drugs

Bio Pharma Dive

MARCH 7, 2023

Rapport Therapeutics aims to find new so-called receptor-associated proteins that could serve as targets for neurological disease medicines. Its most advanced drug is already in early-stage human testing.

Drugs

Drugs Protein Medicine

Pfizer, Roivant set up new company around inflammation drug

Bio Pharma Dive

DECEMBER 1, 2022

The drug is currently in mid-stage testing as a treatment for ulcerative colitis. If it continues to advance, it could be the first approved therapy aimed at a protein known as TL1A, a target multiple other companies are pursuing.

Drugs

Drugs Protein

A biotech shelves its Huntington's drugs after trial failures

Bio Pharma Dive

MARCH 30, 2021

Two drugs developed by Wave Life Sciences didn't appear to have an effect on disease-causing proteins, another setback for Huntington's research after disappointing results last week from Roche and Ionis.

Life Science

Life Science Drugs Protein Trials

Astellas delves deeper into protein degrading drugs with Cullgen deal

Bio Pharma Dive

JUNE 14, 2023

The alliance is Astellas’ second recent partnership involving protein degraders, an emerging area of drug research the company has made a focus in recent years.

Protein

Protein Drugs Research

FDA, in another test of its flexibility, agrees to review Biogen's closely watched ALS drug

Bio Pharma Dive

JULY 26, 2022

Known as tofersen, the drug failed in the main study being used to support its approval. But an apparent effect on a protein of interest in ALS research has Biogen convinced the treatment will pass muster with regulators.

Drugs

Drugs Protein Regulation Research

AC Immune drug fails in blow to another Alzheimer's hypothesis

Bio Pharma Dive

SEPTEMBER 23, 2020

Negative results for the experimental drug semorinemab dents a theory that Alzheimer's disease may be caused by tangles of the protein tau in the brain.

Drugs

Drugs Protein

FDA approves Sanofi’s long-lasting hemophilia drug

Bio Pharma Dive

FEBRUARY 23, 2023

Sanofi and its development partner, Sobi, claim the drug’s once-a-week dosing, and its effect on blood-clotting protein levels, will help it compete in the crowded market for hemophilia A treatments.

FDA Approval

FDA Approval Drugs Protein Marketing

Incyte secures second approval for targeted cancer drug

Bio Pharma Dive

AUGUST 29, 2022

Sold as Pemazyre, the drug, which blocks well-known cancer proteins known as FGFRs, is now also cleared for use in certain patients with very rare and aggressive blood cancers.

Drugs

Drugs Protein

Boehringer, Sosei Heptares team up in schizophrenia drug deal

Bio Pharma Dive

MARCH 11, 2024

Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.

Drugs

Drugs Protein Medicine Development

Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs

Bio Pharma Dive

AUGUST 6, 2024

Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.

Licensing

Licensing Licensing Protein Gene

Genentech takes up a deal to make ‘molecular glue’ drugs

Bio Pharma Dive

SEPTEMBER 20, 2023

Targeted protein degradation has emerged as one of the more competitive areas of pharmaceutical research in recent years as scientists develop new ways to reach difficult-to-drug targets.

Drugs

Drugs Protein Scientist Development

Relay's targeted cancer drug could be safer than its competitors. Is it more effective?

Bio Pharma Dive

OCTOBER 8, 2021

Initial study results for Relay's experimental treatment offer some support for the biotech's protein motion technology, but raise some questions, too.

Protein

Protein Drugs

Putative Fidgetin Like Protein 2 drugs in development, 2024

Pharmaceutical Technology

AUGUST 29, 2024

The Putative Fidgetin Like Protein 2 pipeline drugs market research report outlays comprehensive information on the Putative Fidgetin Like Protein…

Protein

Protein Drugs Development Marketing

Initial launches with $75M and a new idea for targeting problematic proteins

Bio Pharma Dive

MAY 1, 2023

The company was co-founded by, among others, Jamie Cate, husband of CRISPR pioneer Jennifer Doudna, and Kevan Shokat, a chemical biologist whose previous work helped lead to KRAS-targeting cancer drugs.

Protein

Protein Drugs

Myotonin Protein Kinase drugs in development, 2024

Pharmaceutical Technology

AUGUST 29, 2024

GlobalData’s report assesses the drugs in the Myotonin Protein Kinase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein

Protein Development Drugs

Transmembrane Protein PVRIG drugs in development, 2024

Pharmaceutical Technology

AUGUST 29, 2024

GlobalData’s report assesses the drugs in the Transmembrane Protein PVRIG pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein

Protein Development Drugs

No drugs for prions: could new approaches alleviate therapeutic scarcity?

Pharmaceutical Technology

AUGUST 5, 2022

As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent. No progress in drug discovery. “We On the other hand, I think the progress in drug discovery is nil,” comments Requena on the prion disease landscape. And then comes the question of the right target.

Drugs

Drugs Protein Vaccination Vaccine

Bristol Myers pays Agenus $200M for drug aimed at top immunotherapy target

Bio Pharma Dive

MAY 18, 2021

The pharma acquired rights to an experimental antibody medicine that blocks a protein, called TIGIT, that's become a focus for several cancer drugmakers.

Protein

Protein Antibody Medicine Drugs

GSK immunotherapy wins FDA approval, joining crowded cancer drug class

Bio Pharma Dive

APRIL 23, 2021

Jemperli is the seventh drug cleared by the FDA that blocks either PD-1 or PD-L1 proteins, joining Merck's Keytruda, Bristol Myers' Opdivo and others.

FDA Approval

FDA Approval Drugs Protein

AbbVie wagers up to $2B on a Chinese biotech's cancer drug

Bio Pharma Dive

SEPTEMBER 4, 2020

The licensing deal hands AbbVie exclusive rights to a drug that targets CD47, a protein which has caught the attention of other large drugmakers like Gilead and Celgene.

Licensing

Licensing Licensing Drugs Protein

Bristol Myers melanoma drug approved by FDA in immunotherapy advance

Bio Pharma Dive

MARCH 21, 2022

Opdualag is first approved drug that works by targeting a protein called LAG-3 and the third type of "checkpoint inhibitor" the agency has cleared for cancer.

Drugs

Drugs Protein

Annovis looks to advance pivotal Alzheimer’s and Parkinson’s drug studies

Pharmaceutical Technology

OCTOBER 25, 2023

The AD and PD drug aims to reduce the level of neurotoxic proteins, thereby improving information flow across the axonal transport

Drugs

Drugs Protein

Aiolos Bio raises $245M on prospect of better asthma drug

Bio Pharma Dive

OCTOBER 24, 2023

The startup is taking aim at an inflammation-linked protein known as TSLP, which is the target of an approved asthma medicine.

Protein

Protein Medicine Drugs

FDA approves new ALS medicine in precedent-setting decision

Bio Pharma Dive

APRIL 25, 2023

Biogen’s drug failed the key study meant to show it can slow the nerve-destroying disease, but the drug’s effect on a protein of interest led the FDA to conditionally clear it for market.

FDA Approval

FDA Approval Medicine Protein Marketing

E3 Ubiquitin Protein Ligase CBL B drugs in development, 2024

Pharmaceutical Technology

AUGUST 29, 2024

GlobalData’s report assesses the drugs in the E3 Ubiquitin Protein Ligase CBL B pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein

Protein Development Drugs

Superluminal draws RA Capital, Nvidia as investors in GPCR drug hunt

Bio Pharma Dive

AUGUST 28, 2023

GPCRs, a ubiquitous family of proteins that are prime drug targets, have drawn the interest of companies like Structure Therapeutics, Septerna and now Superluminal Medicines.

Drugs

Drugs Protein Medicine

Roche’s surprise study results spur new optimism for TIGIT drugs

Bio Pharma Dive

AUGUST 23, 2023

Data inadvertently published from a closely watched lung cancer study suggest a drug blocking the protein TIGIT may help extend survival, a finding that boosted shares of other developers.

Drugs

Drugs Protein Development

Bromodomain Containing Protein 4 drugs in development, 2023

Pharmaceutical Technology

NOVEMBER 29, 2023

GlobalData’s report assesses the drugs in the Bromodomain Containing Protein 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Containment

Containment Protein Development Drugs

GSK wins US approval for first-of-its-kind blood cancer drug

Bio Pharma Dive

AUGUST 6, 2020

Blenrep is the first multiple myeloma therapy cleared by the FDA that targets BCMA, a protein that's the focus of high-profile drug development efforts.

Drugs

Drugs Protein Development

J&J wins approval of new kind of multiple myeloma drug

Bio Pharma Dive

OCTOBER 26, 2022

It joins a group of medicines on market that target a protein called BCMA. The treatment, which will be sold as Tecvayli, is the first bispecific antibody cleared for the disease.

Protein

Protein Antibody Medicine Drugs

Sanofi drug for rare skin disease, acquired in buyout, fails in late-stage trial

Bio Pharma Dive

SEPTEMBER 9, 2021

The French drugmaker bought Principia Biopharma last year for two therapies that block a protein called BTK. The second targets a much bigger disorder, multiple sclerosis.

Protein

Protein Trials Drugs

AbbVie to buy UK biotech DJS for $255M

Bio Pharma Dive

OCTOBER 20, 2022

The deal gives AbbVie an experimental medicine for idiopathic pulmonary fibrosis, as well as a platform for designing antibody drugs that can target proteins known as GPCRs.

Protein

Protein Antibody Medicine Drugs

Latest Roche results show promise for new type of cancer immunotherapy

Bio Pharma Dive

DECEMBER 10, 2021

Updated Phase 2 data suggested an experimental drug targeting the protein TIGIT could bolster the benefit of Roche's Tecentriq in certain people with advanced lung cancer.

Protein

Protein Drugs

Lilly partners with Sosei to develop drugs aimed at a key family of proteins

Bio Pharma Dive

DECEMBER 16, 2022

The pharma will pay Sosei $37 million upfront to discover new candidates for diabetes and metabolic diseases that target G protein-coupled receptors.

Protein

Protein Development Drugs

Lilly puts more money into protein degradation

ALS drugmakers, encouraged by recent FDA feedback, set their sights on a key protein

Trending Sources

GPCR-targeting drugs: A renewed focus on a ubiquitous group of proteins

Touting a new way to drug an all-important family of proteins, a startup launches with $100M

Gladstone and UCSF scientists discover BET protein role in Covid-19

AbbVie, targeting a well-known protein family, expands a partnership into neuroscience

Feinstein Institutes researchers discover new protein for sepsis treatment

Pfizer stocks cancer drug pipeline with $2.3B deal for Trillium

Teva puts rival to Prometheus, Pfizer drugs at center of turnaround plans

Biogen, Ionis shelve ALS drug following study failure

J&J-backed startup launches with $100M to build better brain drugs

Pfizer, Roivant set up new company around inflammation drug

A biotech shelves its Huntington's drugs after trial failures

Astellas delves deeper into protein degrading drugs with Cullgen deal

FDA, in another test of its flexibility, agrees to review Biogen's closely watched ALS drug

AC Immune drug fails in blow to another Alzheimer's hypothesis

FDA approves Sanofi’s long-lasting hemophilia drug

Incyte secures second approval for targeted cancer drug

Boehringer, Sosei Heptares team up in schizophrenia drug deal

Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs

Genentech takes up a deal to make ‘molecular glue’ drugs

Relay's targeted cancer drug could be safer than its competitors. Is it more effective?

Putative Fidgetin Like Protein 2 drugs in development, 2024

Initial launches with $75M and a new idea for targeting problematic proteins

Myotonin Protein Kinase drugs in development, 2024

Transmembrane Protein PVRIG drugs in development, 2024

No drugs for prions: could new approaches alleviate therapeutic scarcity?

Bristol Myers pays Agenus $200M for drug aimed at top immunotherapy target

GSK immunotherapy wins FDA approval, joining crowded cancer drug class

AbbVie wagers up to $2B on a Chinese biotech's cancer drug

Bristol Myers melanoma drug approved by FDA in immunotherapy advance

Annovis looks to advance pivotal Alzheimer’s and Parkinson’s drug studies

Aiolos Bio raises $245M on prospect of better asthma drug

FDA approves new ALS medicine in precedent-setting decision

E3 Ubiquitin Protein Ligase CBL B drugs in development, 2024

Superluminal draws RA Capital, Nvidia as investors in GPCR drug hunt

Roche’s surprise study results spur new optimism for TIGIT drugs

Bromodomain Containing Protein 4 drugs in development, 2023

GSK wins US approval for first-of-its-kind blood cancer drug

J&J wins approval of new kind of multiple myeloma drug

Sanofi drug for rare skin disease, acquired in buyout, fails in late-stage trial

AbbVie to buy UK biotech DJS for $255M

Latest Roche results show promise for new type of cancer immunotherapy

Lilly partners with Sosei to develop drugs aimed at a key family of proteins

Stay Connected